Alloy RNA Medicine Discovery

Creating transformative RNA medicines leveraging our new proprietary format, AntiClastic™ Antisense Oligonucleotides (AntiClastic™ ASOs).

PROPRIETARY FORMATS FROM ASO PIONEERS

Addressing Unmet Clinical Needs with RNA Medicines

RNA medicine modalities promise to reach intracellular disease targets at the nucleic acid level that are undruggable by conventional modalities. But the success of these therapeutics has been limited by therapeutic index and delivery challenges. Alloy offers foundational technologies and discovery capabilities that address these issues for creating antisense oligonucleotide (ASO) drug candidates.

ENABLING DRUG DISCOVERY OF:

ANTICLASTIC ASO FORMAT

ANTICLASTIC ASO DISCOVERY SERVICES

ANTICLASTIC™ ANTISENSE OLIGONUCLEOTIDES

Alloy’s Proprietary, Widely Applicable Antisense Format for Creating Better Drugs

Leveraging our collaboration with Sudhir Agrawal, a pioneer of antisense technology including gapmer, we have developed an advanced format, AntiClastic™ Antisense Oligonucleotides (AntiClastic™ ASOs), which addresses the limitations of antisense therapeutics. Sudhir is the founder of Arnay Science and the chair of Alloy’s RNA Medicines SAB.

LEARN ABOUT THE PARTNERSHIP

Precise Design

Uses established building blocks, optimal use of 3’- and 5’ ends, and optimal engagement of RNaseH for precise excision.

Improved Potency

Leverages proprietary structures to improve potency and promote the delivery of antisense to target RNA.

Alloy AntiClastic Antisense Oligonucleotides

Better Medicines

Minimizes off-target interactions with unintended RNA targets , mitigates the inflammatory response—thereby improving the therapeutic index.

CASE STUDY

Alloy’s Novel Antisense Format Improves Potency

We have demonstrated significant enhancement in potency by converting known antisense sequences to our proprietary AntiClastic ASO Format.

AntiClastic ASO Format Improved Drug Potency by Up to 25-Fold

ANTICLASTIC ASO DISCOVERY SERVICES

Alloy Discovers the Best AntiClastic ASO Therapeutics for Our Partners

We collaborate closely with our partners to create, improve, and share offerings that enable the discovery of novel AntiClastic ASO therapeutics for your therapeutic pipelines.

Discovery of Antisense Leads in AntiClastic ASO Format

You provide Alloy with the gene target, and we create drugs by applying our bioinformatics solutions and AntiClastic ASO format to discover the lead sequences. We provide guidance and generate preclinical data.

Applying AntiClastic ASO Format to Existing Antisense Sequences

You provide Alloy your lead antisense sequence, and we apply our new AntiClastic ASO format to generate leads with improved potency.

Flexible Project Scopes and Partnership Terms

Our partnership model allows us to share risk and success, while our flexible research and partnership terms offer collaborators of all sizes to access Alloy’s platform and technology with ease.

NOVEL SPATIAL CONFORMATION

Why we call our format AntiClastic

The term AntiClastic describes our innovative strategy of combining the improvements in the primary sequence with a novel spatial conformation of nucleic acid drugs. Our novel structure brings nucleic acids together for an advanced, proprietary format that further enhances the drug-like properties of antisense. (From the Greek anti-, “opposite” and klastos, “broken in pieces”.)

NEWS AND ANNOUNCEMENTS

Alloy Genetic Medicines News & Updates

Learn about our latest product launches and partnership collaborations in genetic medicines .

News and announcements

Alloy RNA Medicines News & Updates

Learn about our latest product launches and partnership collaborations in RNA medicines .

Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases

Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

Let’s make better RNA medicines together

Learn how to get started with our proprietary AntiClastic ASO therapeutic formats or develop a bespoke discovery project together.

Get in touch

Targeting GPCRs with Alloy Antibody Discovery Services

Access the white paper

Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.

G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.

Keyway TCR Mimic Discovery Webinar

Access the webinar recording

I’d like more material about Keyway TCR Discovery

Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Upon filling out this form, you will receive an email with a link to the webinar recording.